{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:01:00Z","timestamp":1781632860323,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Upadacitinib (UPA) is a selective Janus kinase (JAK) 1 inhibitor that may rapidly induce and maintain a remission of inflammatory bowel disease (IBD) through potent suppression of cytokine signaling. While a pan-JAK inhibitor has been shown to increase the risk of thromboembolic and major cardiovascular events (MACE), especially in elderly patients with rheumatoid arthritis, UPA may potentially be a better therapeutic option for elderly IBD patients owing to its selective effect on JAK1. However, the usefulness of UPA in elderly IBD patients has yet to be well assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To explore the efficacy and safety of UPA in elderly IBD patients, we conducted a retrospective case series study of patients with ulcerative colitis (UC) and Crohn\u2019s disease (CD) aged over 60\u2009years who received UPA from December 2022 to March 2025. Clinical response and remission rates, incidence of adverse events, and clinical outcomes were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 8 patients (5 UC and 3 CD) were included in this study. The rate of clinical response in UC was 40% at week 8, 80% at week 16, and the remission rate was 60% at week 16. One patient with acute severe UC underwent colectomy at week 3 due to resistance to UPA, although the patient had also failed a rescue therapy with infliximab (IFX). In patients with CD, the rate of clinical response and remission at week 12 was 33.3% each. After 52\u2009weeks of treatment, 60% of UC and 66.7% of CD patients had sustained UPA treatment. During the median follow-up time of 14.1\u2009months (95% CI 9.2, 24.4\u2009months), adverse events of Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or higher were identified in two cases. Although one patient with UC discontinued UPA at week 36 due to anemia and liver damage, most adverse events observed were otherwise mild. No serious infections, thromboembolic events, MACE, or malignancies were noted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While the small sample size precludes definitive conclusions, this case series suggests that UPA has potential efficacy and relatively acceptable tolerability in elderly patients with IBD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40780-026-00541-x","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T17:34:42Z","timestamp":1768584882000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of Upadacitinib in elderly patients with IBD: a case series"],"prefix":"10.1186","volume":"12","author":[{"given":"Ruby","family":"Arai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyo","family":"Okayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Nishiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Fukata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"541_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1053\/j.gastro.2019.01.002","volume":"156","author":"S Coward","year":"2019","unstructured":"Coward S, Clement F, Benchimol EI, Bernstein CN, Avina-Zubieta JA, Bitton A, et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology. 2019;156:1345\u201353.e4.","journal-title":"Gastroenterology"},{"key":"541_CR2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1186\/s12876-025-04042-3","volume":"25","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Du N, Xu CM, Chen W, Ting Ting C, Xiao Y. Global, regional, and national burden of inflammatory bowel disease in persons aged 60\u201389 years from 1992 to 2021. BMC Gastroenterol. 2025;25:425.","journal-title":"BMC Gastroenterol"},{"key":"541_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4292\/wjgpt.v7.i1.51","volume":"7","author":"D Nimmons","year":"2016","unstructured":"Nimmons D, Limdi JK. Elderly patients and inflammatory bowel disease. World J Gastrointest Pharmacol Ther. 2016;7:51\u201365.","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"541_CR4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.5009\/gnl19209","volume":"14","author":"R Banerjee","year":"2020","unstructured":"Banerjee R, Ali RAR, Wei SC, Adsul S. Biologics for the management of inflammatory bowel disease: a review in tuberculosis-endemic countries. Gut Liver. 2020;14:685\u201398.","journal-title":"Gut Liver"},{"key":"541_CR5","doi-asserted-by":"publisher","first-page":"1089099","DOI":"10.3389\/fmed.2023.1089099","volume":"10","author":"C Herrera-DeGuise","year":"2023","unstructured":"Herrera-DeGuise C, Serra-Ruiz X, Lastiri E, Borruel N. JAK inhibitors: a new dawn for oral therapies in inflammatory bowel diseases. Front Med (Lausanne). 2023;10:1089099.","journal-title":"Front Med (Lausanne)"},{"key":"541_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1136\/flgastro-2023-102400","volume":"15","author":"S Honap","year":"2024","unstructured":"Honap S, Agorogianni A, Colwill MJ, Mehta SK, Donovan F, Pollok R, et al. JAK inhibitors for inflammatory bowel disease: recent advances. Frontline Gastroenterol. 2024;15:59\u201369.","journal-title":"Frontline Gastroenterol"},{"key":"541_CR7","doi-asserted-by":"publisher","first-page":"e13688","DOI":"10.1111\/cts.13688","volume":"17","author":"MF Mohamed","year":"2024","unstructured":"Mohamed MF, Bhatnagar S, Parmentier JM, Nakasato P, Wung P. Upadacitinib: mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17:e13688.","journal-title":"Clin Transl Sci"},{"key":"541_CR8","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","volume":"56","author":"H Nakase","year":"2021","unstructured":"Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021;56:489\u2013526.","journal-title":"J Gastroenterol"},{"key":"541_CR9","doi-asserted-by":"publisher","first-page":"j2099","DOI":"10.1136\/bmj.j2099","volume":"357","author":"J Hippisley-Cox","year":"2017","unstructured":"Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. Bmj. 2017;357:j2099.","journal-title":"Bmj"},{"key":"541_CR10","doi-asserted-by":"crossref","unstructured":"Wu H, Xie T, Yu Q, Su T, Zhang M, Wu L, et al. An analysis of the effectiveness and safety of upadacitinib in the treatment of inflammatory bowel disease: a multicenter real-world study. Biomedicines. 2025;13.","DOI":"10.3390\/biomedicines13010190"},{"key":"541_CR11","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","volume":"388","author":"EV Loftus Jr.","year":"2023","unstructured":"Loftus EV Jr., Panes J, Lacerda AP, Peyrin-Biroulet L, D\u2019Haens G, Panaccione R, et al. Upadacitinib induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2023;388:1966\u201380.","journal-title":"N Engl J Med"},{"key":"541_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/CEG.S367086","volume":"16","author":"M Irani","year":"2023","unstructured":"Irani M, Fan C, Glassner K, Abraham BP. Clinical evaluation of upadacitinib in the treatment of Adults with moderately to severely active ulcerative colitis (UC): patient selection and reported outcomes. Clin Exp Gastroenterol. 2023;16:21\u201328.","journal-title":"Clin Exp Gastroenterol"},{"key":"541_CR13","doi-asserted-by":"crossref","unstructured":"Taxonera C, Garcia-Brenes MA, Machin M, Olivares D, Lopez-Garcia ON, Zapater R, et al. Real-world effectiveness and safety of upadacitinib in patients with ulcerative colitis: a systematic review and meta-analysis. J Clin Med. 2025;14.","DOI":"10.3390\/jcm14072232"},{"key":"541_CR14","doi-asserted-by":"publisher","first-page":"1436183","DOI":"10.3389\/fphar.2025.1436183","volume":"16","author":"S Wang","year":"2025","unstructured":"Wang S, Wang X, Ding J, Zhang X, Zhu H, Fan Y, et al. Disproportionality analysis of Upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system. Front Pharmacol. 2025;16:1436183.","journal-title":"Front Pharmacol"},{"key":"541_CR15","doi-asserted-by":"crossref","unstructured":"Zoe Memel NG, Zou Y, Thiemann A, Dort C, Beck K. Safety of Janus kinase inhibitors for the management of older adults with inflammatory bowel disease. Inflamm Bowel Dis\/Gastroenterol. 2025;3:S43.","DOI":"10.1093\/ibd\/izae282.098"},{"key":"541_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/ard-2022-222259","volume":"82","author":"C Charles-Schoeman","year":"2023","unstructured":"Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2023;82:119\u201329.","journal-title":"Ann Rheum Dis"},{"key":"541_CR17","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.cgh.2024.09.042","volume":"23","author":"M Calafat","year":"2025","unstructured":"Calafat M, Kochar B, Ananthakrishnan AN. A comprehensive review of geriatric syndromes and assessment in older adults with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2025;23:1088\u2013101.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"541_CR18","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/j.cgh.2018.12.032","volume":"17","author":"NZ Borren","year":"2019","unstructured":"Borren NZ, Ananthakrishnan AN. Safety of biologic therapy in older patients with immune-mediated diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17:1736\u201343.e4.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-026-00541-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00541-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00541-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:45:16Z","timestamp":1781631916000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40780-026-00541-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["541"],"URL":"https:\/\/doi.org\/10.1186\/s40780-026-00541-x","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was reviewed and approved by the institutional review board of Tokyo Yamate Medical Center, approval number (235). Opt-out informed consent protocol was used for the use of participant data for research purposes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}